Post-Rebif, Merck KGaA Keeps Faith With MS Therapies

 
• By Kevin Grogan
  
Nerve cells
MS to remain a core area for Merck KGaA • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business